Literature DB >> 9315419

An evaluation of the amount of nonoxynol-9 remaining in the vagina up to 4 h after insertion of a vaginal contraceptive film (VCF) containing 70 mg nonoxynol-9.

C K Mauck1, S Allen, J M Baker, S P Barr, T Abercrombie, D F Archer.   

Abstract

The objectives of this study were to determine the amount of nonoxynol-9 (N-9) remaining in the vagina 30 min and 1, 1.5, 2, and 4 h after vaginal insertion of a single sheet of VCF containing 70 mg N-9 and to compare these results to the manufacturer's instructions for use of this product. A new method of vaginal lavage was used to obtain samples for N-9 determination. This was an open-label, noncomparative, pharmacokinetic study in 12 healthy women volunteers not at risk for pregnancy. The study consisted of a screening visit followed by five test visits approximately 1 month apart and a final visit 1 week after all test visits were completed. At each test visit, the investigator inserted a single sheet of VCF in the vagina of the volunteer at midcycle. The volunteer remained in the clinic and underwent vaginal lavage with normal saline after one of five specified time intervals had elapsed. The sequence of the intervals completed by each volunteer was determined by randomization. When undissolved film was found in the vagina, it was removed prior to lavage and assayed for N-9 content separately from that recovered in lavage fluid. It was assumed that the N-9 in undissolved film would not contribute significantly to sperm immobilization. Between 18.5 and 28.5 mg of N-9 were recovered in lavage fluid after intervals of 0.5, 1, 1.5, and 2 h. These levels did not differ statistically (p > 0.05). The amount of N-9 recovered dropped significantly at 4 h to 11.0 mg. If it is assumed that an N-9 concentration of 0.100 mg/mL is required to immobilize sperm in vitro, this study suggests that the amount of N-9 remaining in the vagina in the form of dissolved film up to 4 h after insertion of VCF is sufficient to immobilize sperm. The lavage procedure may not have recovered all N-9 remaining in the vagina. However, intercourse did not take place between insertion and lavage; if it had, the proportion of the film remaining undissolved and the total amount N-9 remaining in the vagina at the time of examination might have been affected.

Entities:  

Keywords:  Americas; Clinical Research; Clinical Trials; Contraception; Contraceptive Agents--administraction and dosage; Contraceptive Methods; Demographic Factors; Developed Countries; Family Planning; Nonoxynol-9--administraction and dosage; North America; Northern America; Population; Population Dynamics; Research Methodology; Research Report; Spermicidal Contraceptive Agents--administraction and dosage; Time Factors; United States; Vaginal Spermicides

Mesh:

Substances:

Year:  1997        PMID: 9315419     DOI: 10.1016/s0010-7824(97)00100-5

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  6 in total

1.  Detection of the spermicide nonoxynol-9 via GC-MS.

Authors:  Rabi A Musah; Angela L Vuong; Colin Henck; Jason R E Shepard
Journal:  J Am Soc Mass Spectrom       Date:  2012-02-23       Impact factor: 3.109

2.  Development and characterization of bioadhesive vaginal films of sodium polystyrene sulfonate (PSS), a novel contraceptive antimicrobial agent.

Authors:  Sanjay Garg; Kavita Vermani; Alka Garg; Robert A Anderson; William B Rencher; Lourens J D Zaneveld
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

3.  Sodium dodecyl sulfate and C31G as microbicidal alternatives to nonoxynol 9: comparative sensitivity of primary human vaginal keratinocytes.

Authors:  F C Krebs; S R Miller; B J Catalone; P A Welsh; D Malamud; M K Howett; B Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2000-07       Impact factor: 5.191

4.  Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides.

Authors:  Bradley J Catalone; Tina M Kish-Catalone; Lynn R Budgeon; Elizabeth B Neely; Maelee Ferguson; Fred C Krebs; Mary K Howett; Mohamed Labib; Robert Rando; Brian Wigdahl
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

5.  Engineering sperm-binding IgG antibodies for the development of an effective nonhormonal female contraception.

Authors:  Bhawana Shrestha; Alison Schaefer; Yong Zhu; Jamal Saada; Timothy M Jacobs; Elizabeth C Chavez; Stuart S Olmsted; Carlos A Cruz-Teran; Gabriela Baldeon Vaca; Kathleen Vincent; Thomas R Moench; Samuel K Lai
Journal:  Sci Transl Med       Date:  2021-08-11       Impact factor: 17.956

6.  Application and removal of polyanionic microbicide compounds enhances subsequent infection by HIV-1.

Authors:  Vanessa Pirrone; Shendra Passic; Brian Wigdahl; Fred C Krebs
Journal:  Virol J       Date:  2012-01-26       Impact factor: 4.099

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.